Last reviewed · How we verify
SB-715992
At a glance
| Generic name | SB-715992 |
|---|---|
| Also known as | docetaxel |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer (PHASE2)
- A Study of Ispinesib in Metastatic Breast Cancer (PHASE1)
- Study Of Ispinesib In Subjects With Breast Cancer (PHASE2)
- Ispinesib In Combination With Carboplatin In Patients With Solid Tumors (PHASE1)
- SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (PHASE2)
- SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer (PHASE2)
- Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer (PHASE2)
- SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB-715992 CI brief — competitive landscape report
- SB-715992 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI